<DOC>
	<DOCNO>NCT00915850</DOCNO>
	<brief_summary>This phase I/II study conduct determine maximum-tolerated dose ( MTD ) , dose-limiting toxicity ( DLT ) , efficacy combination chemotherapy use docetaxel , cisplatin 5-fluorouracil ( DCF ) unresectable advanced esophageal cancer . The usefulness regimen evaluate RECIST , time progression median survival time .</brief_summary>
	<brief_title>Trial Docetaxel , Cisplatin , Fluorouracil ( 5-FU ) Unresectable Advanced Esophageal Squamous Cell Carcinoma ( ESCC )</brief_title>
	<detailed_description>&lt; Phase I &gt; Primary Objective : To establish safety combination chemotherapy comprise docetaxel ( escalate dos : 25,30,35,40 mg/m2 , day1 day8 ) , cisplatin ( 12mg/m2 , day1-5 ) , fluorouracil ( 600mg/m2 , day1-5 ) ( DCF ) unresectable advanced esophageal cancer . Secondary Objective : To observe efficacy regimen patient . &lt; Phase II &gt; Primary Objective : To assess response rate combination chemotherapy comprise docetaxel ( recommend dose determined phase I study , day1 day8 ) , cisplatin ( 12 mg/m2 , day1-5 ) , fluorouracil ( 600 mg/m2 , day1-5 ) ( DCF ) unresectable advanced esophageal cancer . Secondary Objectives : To determine adverse reaction regimen patient . To determine TTP ( Time progression ) patient treat regimen . To determine MST ( Median survival time ) patient treat regimen .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>locally advanced metastatic esophageal cancer preclude curative surgical resection recurrent esophageal cancer measurable disease CT scan ECOG performance status 01 20 year old Patients must clinically document unresectable metastatic esophageal cancer histologic confirmation diagnosis tumor Tissue tumor must available Patients must measurable disease Patients may receive prior adjuvant chemotherapy ; must complete least 1 month Life expectancy &gt; 3 month Laboratory value follow 3000/mm3 &lt; WBC &lt; 12000/mm3 1500/mm3 &lt; granulocyte count 8.0 gm/dl &lt; hemoglobin Platelet count &gt; 100000/mm3 Aspartate transaminase &lt; 150 IU/L Alanine transaminase &lt; 150 IU/L Creatinine &lt; 1.5 mg/dl Able willing give valid write informed consent Pregnancy ( woman childbearing potential : refusal inability use effective mean contraception ) Active uncontrolled infection Prior chemotherapy radiation therapy within 4 week , surgery within 3 week immunotherapy within 1 week Clinically significant heart disease Patients history myocardial infarction within previous three month Patients uncontrolled diabetes mellitus hypertension Presence clinically apparent central nervous system metastases Patients severe concurrent disease , judgment investigator , would make patient inappropriate entry study Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>